Tag Archives: Alethia Young

Credit Suisse Thinks Gilead Sciences’ Stock is Going to Recover

468785.png

Credit Suisse analyst Alethia Young maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) on February 27 and set a price target of $79. The company’s shares closed yesterday at $70.48, close to its 52-week low of $65.38. According to

Analysts Offer Insights on Healthcare Companies: Alexion Pharmaceuticals (NASDAQ: ALXN), Quest Diagnostics Inc (NYSE: DGX) and Icon plc (NASDAQ: ICLR)

467569.jpg

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alexion Pharmaceuticals (NASDAQ: ALXN), Quest Diagnostics Inc (NYSE: DGX) and Icon plc (NASDAQ: ICLR). Alexion Pharmaceuticals (NASDAQ: ALXN) In a report released yesterday,

Regeneron Receives a Buy from Credit Suisse

466853.jpg

Credit Suisse analyst Alethia Young maintained a Buy rating on Regeneron (NASDAQ: REGN) yesterday and set a price target of $485. The company’s shares closed yesterday at $360. According to TipRanks.com, Young is a 1-star analyst with an average return

Amgen Inc Receives a Hold from Credit Suisse

466257.gif

In a report issued on February 3, Alethia Young from Credit Suisse maintained a Hold rating on Amgen Inc (NASDAQ: AMGN), with a price target of $178. The company’s shares closed last Friday at $167.53. According to TipRanks.com, Young is

Credit Suisse Maintains a Hold Rating on Biogen Inc

462946.png

In a report released yesterday, Alethia Young from Credit Suisse maintained a Hold rating on Biogen Inc (NASDAQ: BIIB), with a price target of $312. The company’s shares closed yesterday at $285.59. According to TipRanks.com, Young is ranked 0 out

How Much Eli Lilly (LLY)’s Sola Failure Will Cost Biogen Inc. (NASDAQ:BIIB)?

LLY’s Sola failure costs Biogen Inc. (NASDAQ:BIIB), will it recover?

Shares of Biogen Inc. (NASDAQ: BIIB) dropped by 12% in a single day in reaction to the recent selloff of Eli Lilly (LLY) shares, which was triggered by the failure of LLY’s Alzheimer’s drug solanezumab (sola) phase III trial. The shares